Navigation Links
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
Date:7/30/2009

. Few clinical trials are under way to identify treatment recommendations, and no new drugs have been assessed for this disease in many years.

"Patients with Mycobacterium avium complex or Mycobacterium abscessus lung disease have limited options, which is why we welcome the opportunity to collaborate with NIAID to study this new treatment," said Renu Gupta, MD, Transave's Executive Vice President for Development and Chief Medical Officer. "ARIKACE is an excellent candidate to study in these infections based on the successful Phase II results in treating other chronic lung infections, where it demonstrated sustained release in the lung with minimal systemic exposure."

About ARIKACE(TM)

ARIKACE is a sustained-release formulation of the antibiotic amikacin, which encloses the drug in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), neutral liposomes that enable penetration of the biofilm and are highly efficient, with a very low lipid-to-drug ratio (0.65). ARIKACE can be delivered through nebulization, which enables the small aerosol droplet size (1 to 5 microns) to facilitate more effective distribution in the lungs.

Positive Phase II results were announced in June 2008 from a clinical trial in European CF patients with Pseudomonas lung infections. The company also previously announced completion of enrollment in two additional Phase II trials including a study where ARIKACE is being evaluated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections and a second trial in U.S. CF patients with Pseudomonas lung infections.

ARIKACE has bee
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Transave, Inc. Secures $12.5 Million in New Financing
2. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
3. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
4. NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling
5. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
6. The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding
7. Delcath Enters Agreement to Sell 869,565 Units
8. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
9. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
10. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
11. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... 2013  Rahal Letterman Lanigan Racing (RLL) and StemCyte, ... cell banking and therapeutics, announced today that StemCyte has ... Stairlifts Indy car driven by James Jakes ... IZOD IndyCar 2013 season.   StemCyte, Inc. and ... awareness of umbilical cord blood banking and its educational ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... high-tech economy has yet to hit its growth spurt ... executives, Madison has what it takes to support a ... as successful as other regions? , , Accelerate Madison ... business climate through information technology, hosted a forum to ...
... Im not a big Bob Dylan fan, but lately I ... in the Wind" in which he questions mans inability ... , ,Dylans lyrics come to mind whenever the media starts ... business reengineering was all the rage. Anyone hesitating to reengineer ...
... an ancient and proud history of interstate sports rivalries ... like this past New Years Day, the rivalry generates ... and marijuana have in common? They both get smoked ... fomenting another interstate rivalry. This one is of keen ...
Cached Biology Technology:Tech Business Leaders Compare Madison to Other Regions 2Tech Business Leaders Compare Madison to Other Regions 3Tech Business Leaders Compare Madison to Other Regions 4Offshore Outsourcing: On Target or Off Base? 2Offshore Outsourcing: On Target or Off Base? 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 2For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 4
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... have determined the atomic structure of the ,binding, between ... key to treating patients with diseases such as variant ... a family of rare progressive neurodegenerative disorders, called prion ... thought that those who have developed vCJD became infected ...
... Sea the deepest point on Earth are ... according to Shahrazad Abu Ghazleh and colleagues from the ... Sea-Red Sea or Mediterranean-Dead Sea Channels therefore need a ... its former level, in order to sustainably generate electricity ...
... antiretroviral drugs in hair samples taken from HIV patients ... findings, published in the February 20 issue of ... in the hair of patients on treatment correlated strongly ... "High levels of antiretrovirals in hair correlated with ...
Cached Biology News:Antibody key to treating variant CJD, scientists find 2Is the Dead Sea dying? 2Using hair to manage HIV/AIDS and predict treatment success 2Using hair to manage HIV/AIDS and predict treatment success 3
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
... A - Fixation medium Reagent B - ... for fixing cells in suspension with Reagent ... Reagent B. This procedure gives antibodies access ... scatter characteristics of the cells intact. Specific ...
... Vision Mount is formulated for covering tissue sections and ... alcohol insoluble end products. , ... ... as Fast-Red or AEC that require an aqueous mounting medium, ...
... Retrieval Solution, High pH This pH ... retrievel prior to immunohistochemical staining procedures. It ... sections mounted on glass slides. For particular ... is especially effective. It should be noted ...
Biology Products: